Table 2B.

Hematopoietic recovery, Acute and Chronic GVHD: BMT CTN 0501 (TCF regimen) compared to Non-trial TCF regimen and Non-trial regimens

Outcome	Trial TCF regimen	Non-trial TCF regimen	Non-trial TBI regimens	Non-trial chemotherapy only
Neutrophil recovery	69% (60 – 78)	74% (63 – 84) p-value NS	65% (59 – 72) p-value NS	68% (60 – 76) p-value NS
Platelet recovery	75% (65 – 83)	80% (68 – 89) p-value NS	68% (62 – 75) p-value NS	64% (55 – 73) p-value NS
Acute GVHD
Grade II – IV	47% (37 – 57)	66% (54 – 78) p=0.01	34% (28 – 41) p=0.04	31% (23 – 40) p=0.02
Grade III – IV	17% (10 – 25)	28% (17 – 40) p-value NS	16% (12 – 22) p-value NS	18% (12 – 25) p-value NS
Chronic GVHD	43% (33 – 53)	37% (25 – 50) p-value NS	32% (25 – 38) p-value NS	31% (23 – 40) p-value NS

Abbreviation:

GVHD = graft versus host disease

TCF = total body irradiation (1320 cGy), cyclophosphamide (120 mg/kg), fludarabine (75 mg/m²)